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Introduction
At present, CD34 ϩ cells obtained from peripheral blood (PB) represent the major source for stem cells used in hematopoietic autologous transplants. 1 The frequency at which CD34 ϩ hemopoietic stem and progenitor cells (HPC) are usually present in the PB of normal individuals is low. 2, 3 However, it has been shown that in vivo administration of cytokines alone or in combination with chemotherapy, induces a transient expansion of the CD34 ϩ HPC compartment in the PB. 4 lection of PB mononuclear cells during this period through one or more leukapheresis sessions allows a number of CD34 ϩ HPC to be obtained which usually guarantees the success of hematopoietic recovery once the cells are reinfused after intensive chemotherapy. 6, 7 From all cytokines initially tested for mobilization, granulocyte colony-stimulating factor (G-CSF) and granulo-monocyte (GM)-CSF are the most widely used, not only for autologous but also for allogeneic transplants. [8] [9] [10] [11] In spite of this, a relatively significant proportion of patients show defective CD34 ϩ cell mobilization responses to conventional protocols in which either G-CSF or GM-CSF are used. 12, 13 Stem cell factor (SCF), a ligand for the receptor encoded by the c-kit protooncogene, is one of the most active hematopoietic growth factors with a broad range of activity in both undifferentiated and mature hematopoietic cells. Accordingly, SCF has been shown to promote proliferation and differentiation of early progenitor cells, as well as to increase their survival, while at the same time exerting its effects on mature mast cells from different tissues. 14, 15 Previous studies have shown that once administered in combination with other cytokines such as G-CSF, SCF has a synergistic effect on enhancing mobilization of CD34 ϩ HPCs into the PB. 16 Accordingly, accumulating evidence exists that the combined use of G-CSF and SCF is associated with higher mobilization rates as compared to G-CSF alone. [17] [18] [19] Moreover, SCF has become an alternative agent in patients who show a poor response to other mobilization protocols. Although the biological and clinical effects of SCF administration have been extensively explored, 14, 20 information is still scanty on the impact of administration of SCF combined with other cytokines and/or chemotherapy on the relative composition of both the CD34 ϩ and CD34 Ϫ cell subsets some of which have a potentially important role in predicting the outcome of either autologous or allogeneic transplants; these include the subsets of more immature CD34 ϩ HPC and DC, among others. 21, 22 The aim of the present study was to gain further insights into the effects of the use of SCF in combination with G-CSF and cyclophosphamide. For that purpose, we have explored in a homogeneous group of 22 uniformly treated breast cancer patients: (1) the kinetics of mobilization of both CD34 ϩ and CD34 Ϫ cell subsets, including DC, in PB samples sequentially obtained from day ϩ7 to day ϩ12 after mobilization; and (2) the composition of the CD34 ϩ and CD34 Ϫ cell fractions present in the leukapheresis products (LP) obtained either at days ϩ10 and ϩ11 or ϩ11 and ϩ12 after mobilization.
A total of 22 female patients diagnosed with breast cancer who had previously received six or more cycles of chemotherapy were included in the present study. Inclusion criteria were: age 18-65, ECOG performance status 0-2, diagnosis of high risk breast cancer (stage II and stage III with four or more lymph nodes involved) or metastatic disease without BM involvement, and normal liver, cardiac, respiratory and renal function. Patients were mobilized with cyclophosphamide (3 g/m 2 /day) on day ϩ1, followed by SCF (20 g/kg/day, kindly provided by Amgen, Thousand Oaks, CA, USA) and G-CSF (5 g/kg/day) administered daily from day ϩ2 to the last day of leukapheresis. G-CSF was given immediately prior to SCF administration, both by the subcutaneous route. Due to the potential direct effect of mast cell stimulation, all patients received a premedication regimen consisting of oral cetirizine (10 mg), ranitidine (300 mg) plus two puffs of albuterol metered-dose inhaler, 24 h prior to the first dose of SCF and thereafter 1 h prior to each injection of SCF.
Leukapheresis procedures were performed on 2 consecutive days after the cyclophosphamide-induced nadir, starting from day ϩ10 onwards, as soon as the white blood cell count (WBC) was у7.5 ϫ 10 9 /l. 17, 23 In practice, leukapheresis started at day ϩ11 in all cases except for three that began stem cell harvest at day ϩ10. Leukapheresis was performed using a blood cell separator (Fenwal CS-3000 plus; Baxter Healthcare Corporation, Deerfield, IL, USA) with ACD-A as anticoagulant (9:1). The flow rate was 55-65 ml/min and a total of 2-3 blood volumes were processed over 4 h. A total of eight samples per patient were sequentially analyzed; six corresponded to PB obtained at days ϩ7, ϩ8, ϩ9, ϩ10, ϩ11 and ϩ12 after mobilization and the others to LP obtained either at days ϩ10 and ϩ11 (n ϭ 3) or at days ϩ11 and ϩ12 (n ϭ 19). PB samples (5 ml each) were obtained by venipuncture in tubes containing tripotassium ethylene-diaminetetraacetic acid (K 3 EDTA) as anticoagulant. For the study of the LP, 0.5 ml was transferred into a tube containing lyophilised heparin as anticoagulant to prevent sample dilution, which could affect the enumeration of CD34 ϩ HPC absolute counts. Samples were collected at three different hospitals (Hospital Clínico de Valencia, Valencia, Hospital Sant Pau i Sant Creu, Barcelona and Hospital 12 de Octubre, Madrid, Spain) kept at RT (22-23°C) and processed within the first 18 h after collection at a central laboratory (Servicio de Citometría, Universidad de Salamanca, Salamanca, Spain).
Sample preparation Standard protocol for enumeration of CD34
ϩ HPC: Sample preparation, flow cytometry data acquisition and analysis were performed as described by Gratama et al. 24 Briefly, 10 l of anti-CD45 conjugated with fluorescein isothiocyanate (FITC) (HI30; Caltag Laboratories, San Francisco, CA, USA) and 10 l of anti-CD34 conjugated with phycoerythrin (PE) (HPCA-2; Becton Dickinson Biosciences (BD), San Jose, CA, USA) monoclonal antibodies (MoAb) were added to the bottom of a 12 ϫ 75 mm polystyrene tube, followed by either 100 l of pre-mixed PB or 10 l of pre-mixed LP. Following a 15 min incubation (RT) of the sample with the MoAb mixture, 2 ml of the fixative-free Quicklysis lysing reagent (IMICO, Madrid, Spain) was added and a further 10 min incuLeukemia bation at RT was performed. Then, either 100 l or 10 l of pre-mixed Flow-Count bead suspension (Beckmann Coulter, Miami, FL, USA) was added for PB and LP samples, respectively, immediately prior to data acquisition. Finally, the stained sample was gently mixed and data acquisition performed. As recommended by Gratama et al, 24 both the sample and counting beads were aliquoted using the reverse pipetting technique.
Data acquisition was performed using a FACSCalibur flow cytometer equipped with CellQuest software (BD). The FSC threshold was set at a sufficiently low level so as not to exclude the counting beads. A Boolean gating strategy was employed for list mode data analysis using the CellQuest software as previously described in detail. 24 In order to verify the accuracy of the CD34 ϩ absolute cell numbers obtained, in one randomly selected sample per patient the assay was performed in parallel using Flow-Count beads and TruCount tubes (BD). Intralaboratory variability for both techniques as regards the enumeration of absolute counts of CD34 ϩ HPC showed in all patients tested, a coefficient of variation of Ͻ5%.
Immunophenotypic analysis of PB recovery of CD34
Ϫ hemopoietic cell populations and dendritic cell subsets:
In all 22 patients, two different immunofluorescence four-colour stainings were performed daily in each PB sample obtained from day ϩ7 to day ϩ12 after starting mobilization. In both stainings, a mixture of FITC-conjugated MoAbs was used directed against T cells (CD3; clone: Leu-4, BD), B lymphocytes (CD19; clone: Leu-12, BD), natural killer (NK) cells (CD56; clone: C5.9, IMICO), monocytes (CD14; clone: Leu-M3, BD), and CD34
ϩ HPCs (CD34; clone: HPCA-2, BD), together with anti-HLADR conjugated to peridin chlorophyll protein (PerCP) (clone:L243, BD) and CD123 conjugated to allophycocyanine (APC) (clone: 9F5, BD); PE-conjugated CD16 (clone: Leu-11c, BD) was used in one of the MoAb combinations while it was replaced by CD33-PE (clone: Leu-M9, BD) in the second.
Sample preparation was performed as described above for the enumeration of CD34 ϩ HPC except that after lysing, the erythrocytes cells were washed once in PBS and resuspended in 0.5 ml of PBS containing 1% paraformaldehyde. 25 Data acquisition was performed immediately after completion of sample preparation in two consecutive steps using a FACSCalibur flow cytometer and the CellQuest software (BD). Firstly, information on 2 ϫ 10 4 events/test, corresponding to the whole PB cellularity was collected and stored. In a second step, information was stored exclusively for those cells
live gate. In this step, a minimum of 3 ϫ 10 5 events from the total PB cellularity was measured in order to obtain information on at least 1000 dendritic cells defined as being MHC II ϩ /lineage Ϫ cells (non-T, non-B, non-NK and non-monocytic cells) for further immunophenotypic analysis. 26 For data analysis, the Paint-A-Gate PRO software was used. Identification and enumeration of the relative numbers of the different CD34
Ϫ cell subsets present in PB was performed as shown in Figure 1 .
Absolute counts were derived by multiplying the percentage of each cell subset from the total number of PB nucleated cells by the nucleated cell count obtained in a Cell Dyn 4000 hematologic cell counter (Abbott, Santa Clara, CA, USA) for the same sample. 
Flow cytometric immunophenotypic analysis of CD34
ϩ HPC subsets present in both leukapheresis samples and peripheral blood and CD34
Ϫ hematopoietic cell subsets present in leukapheresis samples:
For this purpose, 10 different fourcolor parallel stainings were carried out on PB obtained at day ϩ10 and LP obtained at day ϩ11 and day ϩ12 in a group of eight patients. In each of the 10 four-color staining combinations of MoAb directly conjugated with FITC, PE, PerCP or PE-cyanine 5 (PC5) and APC were (1) Once obtained, leukapheresis samples were immediately diluted in phosphate-buffered saline (PBS, pH 7.6) to reach a final concentration of 2 ϫ 10 7 mononuclear cells (MNCs)/ml and sample preparation was performed as described above. For the combined staining of surface and intracellular antigens (stainings 7 to 10), staining of surface antigens was followed by fixation, permeabilization and staining of intracellular markers using the Fix & Perm reagent kit (Caltag), according to previously described protocols. 27 In all cases data acquisition was performed on a FACSCalibur flow cytometer (BD) using a previously described double-step acquisition procedure. 2 Firstly, information on 3 ϫ 10 4 events corresponding to the total cellularity of the LP samples was collected and stored; in a second step, information was stored exclusively for those cells included in a live gate containing at least 1000 CD34 ϩ cells. The CellQuest and Paint-A-Gate PRO software programs (BD) were used for data acquisition and data analysis, respectively. In all samples both the percentage and absolute counts of CD34 ϩ and CD34 Ϫ cell subpopulations were assessed as described above. Antigen expression was evaluated both as the presence or absence of reactivity for a specific marker and its mean fluorescence intensity expressed in fluorescence channels scaled from 0 to 10 000 (arbitrary units).
Statistical analysis
Mean values and their standard deviation as well as median values, the 25th and 75th percentiles and range were calculated for each variable by using the SPSS software program (SPSS 6.1.2, Chicago, IL, USA). In order to explore the statistical significance of differences found between groups, the paired Wilcoxon's non-parametric test (SPSS 6.1.2) was used. Differences were considered to be statistically significant when P values were Ͻ0.05.
Results

Sequential analysis of the CD34
ϩ hemopoietic progenitor cells and CD34
Ϫ subpopulations in PB samples Table 1 shows the relative and absolute counts of CD34 ϩ HPC present in PB from the 22 breast cancer patients included in the present study. Both the frequency and absolute counts of PB CD34
ϩ HPC significantly (P Ͻ 0.05) increased from day ϩ7 to day ϩ9 after mobilization; on day ϩ10 the proportion of CD34 ϩ cells reached a plateau while the absolute counts went on increasing.
The CD34 Ϫ major leukocyte subsets in PB were identified by multiparametric flow cytometry as described in Figure 1 . The sequential analysis of these CD34
Ϫ cell subsets showed the existence of significant changes on their distribution over time ( Table 2 and Figure 2) . Accordingly, from day ϩ7 on, a significant increase was observed in the absolute counts of all leukocyte subsets except for basophils, which decreased from day ϩ9 on. Interestingly, between day ϩ7 and day ϩ8 this increase was pronounced for monocytes while it was only mild for neutrophils and other CD34 Ϫ cell subsets (Table 2 ). Regarding the percentage of lymphocytes, eosinophils and basophils, they decreased from day ϩ7 up to day ϩ12, while neutrophils tended to increase during this period and monocytes increased up to day ϩ9 and then decreased.
Regarding DCs, the absolute number of CD16 ϩ DC and subsequently the total DC increased from day ϩ9 up to day ϩ12. Otherwise, the relative numbers decreased from day ϩ7 up to day ϩ10 (P Ͻ 0.03) (Figure 2 ) remaining stable thereafter. The other DC subpopulations (CD33 high and CD123 high ) did not show any significant changes although their absolute numbers tended to increase on day ϩ12.
Comparative analysis of the subsets of CD34
ϩ HPCs and CD34
Ϫ leukocyte populations present in the LP As shown in Table 3 , the number of CD34 ϩ HPC present in the LP did not differ between the first and second samples. 
) CD34
ϩ HPC was significantly higher on the first LP (P ϭ 0.04). Interestingly, once the frequency of these subsets of CD34
ϩ HPC from LP were compared to that of a PB sample obtained one day in advance, slight differences were observed as reflected by a higher proportion of early CD34 ϩ HPC and a lower erythroid CD34 ϩ HPC/myeloid CD34 ϩ HPC ratio (P ϭ 0.02) A comparative analysis of the composition of CD34 Ϫ leukocyte populations in the two consecutive LP is shown in Figure  3 . Significantly higher percentages (P ϭ 0.002) and absolute numbers (P ϭ 0.009) of DC were found in the second LP. The other CD34
Ϫ cell subsets did not show significant changes between both LP. However, the ratio between the number of neutrophils and monocytes significantly decreased from the first LP to the second one (P ϭ 0.007).
Discussion
In the present paper, based on the study of a homogeneous group of 22 breast cancer patients, we have confirmed previous observations 16 indicating that a high number of CD34 ϩ PB HPC can be obtained with a mobilization protocol based on SCF plus G-CSF and cyclophosphamide. The median number of total CD34 ϩ HPC harvested in one leukapheresis session was 13 Ϯ 13 ϫ 10 6 CD34 ϩ cells/kg body weight and therefore much higher than reported for cyclophosphamide plus G-CSF in the absence of SCF. 28, 29 Accordingly, infusion of a single LP obtained with this mobilization protocol would ensure a permanent and rapid hematological recovery without risk of delayed platelet engraftment after transplantation. [30] [31] [32] Despite the fact that the absolute number of PB CD34 ϩ cells showed a progressive increase from day ϩ7 to day ϩ10, identical numbers of CD34 ϩ cells/kg body weight were collected in the first and second leukapheresis sessions. These findings support previous observations indicating that in breast cancer patients treated with this mobilization protocol, the CD34 peak generally occurs between days ϩ10 and ϩ12. 23 At present, information on the effects of SCF administered in combination with G-CSF and cyclophosphamide on the CD34 Ϫ PB leukocyte subsets is scanty. 28 It has been reported 33, 34 that myeloablative effects of cyclophosphamide are still evident at days ϩ7 and ϩ8. This could explain why despite the combination with SCF, the absolute number of PB neutrophil counts remained low and stable from day ϩ7 to day ϩ8. By contrast, the number of monocytes clearly increased, between these 2 days and predicted, 1 day in advance, neutrophil recovery. Since neutropenia probably represents the most important adverse effect of mobilization protocols in which chemotherapeutic agents are used, the availability of a simple, rapid and easy to assess parameter such as the increase in the absolute number of PB monocytes might be of great clinical utility for predicting neutrophil recovery. In line with this, in a recent study on chemotherapyrelated aplasia in acute leukemias we have also found that the increase in PB monocytes predicts neutrophil recovery from 24 h to 48 h. 35 However, to the best of our knowledge, no study has been reported in which the number of PB monocytes in SCF-mobilized patients has been sequentially analyzed as a potential predictor for neutrophil recovery. Overall, these results would suggest that early monocyte recovery in patients mobilized with cyclophosphamide, G-CSF and SCF would not be specifically attributable to the mobilizing agents but would just reflect the different recovery kinetics for monocytes and neutrophils.
From day ϩ8 on, all PB CD34 Ϫ leukocyte subsets, including neutrophils, dramatically increased in parallel to the number of circulating CD34 ϩ HPCs except for basophils which showed a continuous decrease from day ϩ10 onwards, probably indicating that these cells could rapidly migrate from PB to other tissues. In recent years, interest on DC in the transplantation setting have increased due to their role as antigenpresenting cells. To date, up to three different DC subsets have been identified in PB. Although the exact role of these DC still remains to be established, preliminary studies 36 suggest that they would be responsible for triggering different T cellmediated immune responses. Accordingly, CD123
high lymphoplasmocytoid DC could specifically trigger a Th 2 -based T cell response while CD33 high myeloid DC would preferentially stimulate Th 1 T lymphocytes; the exact role of CD16 ϩ antigenpresenting cells still needs to be clarified.
In the present study, DC showed a rapid increase in absolute numbers from day ϩ9 on, while at the same time their relative number decreased. This was mainly due to changes in the CD16 ϩ DC subset, since the number of other DC subpopulations (CD33 high and CD123 high ) were very low. In recent years, several studies have reported the potential origin and role of these CD16 ϩ cells. Accordingly, Ziegler-Heitbrock et al 37 suggests that these cells correspond to a minor subset of CD14 low monocytes-derived cells while Schakel et al 38 clearly show that they functionally act as antigen-presenting cells. The specific increase in the number of these CD16 ϩ antigenpresenting cells would suggest that SCF in addition to G-CSF Results are expressed as mean ± standard deviation (range is shown in brackets).
Leukemia is a potent inducer of the production of these but not other DC subsets. 39 Further studies are necessary to clarify the clinical significance of the increase in CD16 ϩ cells in this context. Whenever a new protocol is used for the mobilization of CD34 ϩ HPC, the criteria employed to establish timing of the leukapheresis sessions are commonly based on the overall number of CD34 ϩ cells collected during leukapheresis. However, since CD34 ϩ cells represent a heterogeneous cell population where more mature lineage-committed progenitors coexist with stem cells responsible for long-term engraftment, it is also important to determine the relative composition of the CD34 ϩ cell population. In this sense, it was our aim to compare the relative composition of the CD34 ϩ HPC obtained in the first and second leukapheresis sessions. Interestingly, no major differences were detected between LP as regards both the number of early and lineage-committed progenitors, except for a decreased ratio between the CD34 ϩ cells displaying an erythroid and myeloid phenotype on the second leukapheresis. Interestingly, both the relative numbers of immature CD34
ϩ HPC and the percentage of myeloid-committed progenitors were higher the day prior to the leukapheresis than in the LP. Overall, these results would suggest that at the earliest mobilization periods, PB CD34 ϩ HPC would contain higher percentages of immature uncommitted progenitors, their frequency decreasing once the CD34 peak in PB is achieved; the differences observed in the ratio between erythroid-and myeloid-committed CD34 ϩ HPC probably reflects different kinetics of either production and/or BM homing for the two CD34 ϩ cell subsets. To the best of our knowledge, no study has been reported in which the distribution of CD34 ϩ cell subsets in patients mobilized with SCF is compared to that of G-CSF-mobilized individuals. In spite of this, our results show higher frequencies of immature uncommitted CD34 ϩ /CD38 Ϫ /CD90 ϩ HPC as compared to other series in which G-CSF-mobilized individuals have been studied. 40, 41 However, such a comparison has to be made with caution due to the fact that significantly different technical protocols were employed, including the use in our study of more sensitive fluorochrome-conjugated reagents to assess CD38 expression. In this sense, further Results are expressed as mean ± standard deviation (range is shown in brackets). PB, peripheral blood: LP, leukapheresis products; lo, low fluorescence intensity. P value obtained from multiple comparisons among different days. a differences between that day and the next one: P = 0.04; b differences betwen that day and the next one: P Ͻ 0.03.
prospective studies in which both groups of individuals are studied in parallel are necessary to establish the exact clinical and biological significance of our observations on the effects of SCF.
Upon analysing the relative composition of CD34 Ϫ leukocyte subsets in the two LP, we observed a significant increase in the number of CD16 ϩ DC on the second LP, while the neutrophil/monocyte ratio decreased. No significant differences were detected for the other CD34 Ϫ leukocyte subsets. The higher neutrophil/monocyte ratio found on the first LP could probably reflect the existence of less differentiated neutrophils at this time point which would display a similar density to that of mononuclear cells isolated during the leukapheresis procedure. This notion would be supported by the fact that changes observed in this ratio are mainly due to the existence of decreased absolute neutrophil numbers in the second LP.
In a recent study, Fearnley et al 39 have shown that the number of PB DC is reduced at the time when CD34 ϩ cells are harvested after mobilization with G-CSF alone or in combination with cyclophosphamide. More recently, Arpinati et al 42 demonstrated that G-CSF treatment selectively increases the number of CD123 high lymphoid-plasmocitoid DCs in PB but not the number of CD33 high myeloid DCs. However, in both studies only CD16 Ϫ DC were analyzed. As mentioned above, in the present study we found significantly higher numbers of CD16 ϩ DCs in the second LP collected. No differences were observed in the composition for the other CD16 Ϫ DC. Since DCs are highly specialized antigen-presenting cells of the immune system, it is clear that monitoring DC counts may
Figure 3
Comparative analysis of the distribution of both major and minor CD34 − leukocyte subsets present in leukapheresis products obtained at day +11 and day +12 after mobilization with SCF plus G-CSF and cyclophosphamide. Results are expressed as percentage (a and c) and absolute counts (b and d). Statistically significant differences were only observed between leukapheresis products obtained at differents days for the relative * (P = 0.002) and absolute numbers of dendritic cells ** (P = 0.009).
be clinically useful both in protocols aimed at their specific isolation for immunotherapeutic purposes such as vaccination, and because DCs play an important role as APC in graft rejection in allogeneic transplants.
In summary, this protocol is highly effective for stem cell mobilization. Regarding the kinetics of PB mobilization, our results show that monitoring of monocytes would predict for neutrophil recovery and that a rapid increase of DC occurs from day ϩ9 on. As far as the composition of leukapheresis is concerned, no major differences were observed between the two harvests except for a significant increase in DC and the monocyte/neutrophil ratio on the second LP.
